BTIG Research Raises Theravance Biopharma (NASDAQ:TBPH) Price Target to $25.00

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) had its target price raised by equities researchers at BTIG Research from $24.00 to $25.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the biopharmaceutical company's stock. BTIG Research's price objective would suggest a potential upside of 126.65% from the stock's previous close.

A number of other research firms also recently weighed in on TBPH. Jones Trading upgraded Theravance Biopharma to a "strong-buy" rating and set a $24.00 target price for the company in a research report on Tuesday, June 17th. Wall Street Zen upgraded Theravance Biopharma from a "hold" rating to a "buy" rating in a report on Saturday, June 21st. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $16.60.

Theravance Biopharma Stock Performance

Shares of NASDAQ:TBPH traded down $0.19 on Friday, hitting $11.03. The company's stock had a trading volume of 208,255 shares, compared to its average volume of 263,130. The company has a market capitalization of $551.51 million, a price-to-earnings ratio of -9.35 and a beta of -0.09. Theravance Biopharma has a 12 month low of $7.44 and a 12 month high of $11.82. The stock's 50-day moving average is $10.00 and its two-hundred day moving average is $9.50.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.16). The company had revenue of $15.39 million for the quarter, compared to the consensus estimate of $28.08 million. Theravance Biopharma had a negative return on equity of 32.37% and a negative net margin of 89.38%. Equities analysts expect that Theravance Biopharma will post -1.09 earnings per share for the current fiscal year.

Insider Activity at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 24,000 shares of Theravance Biopharma stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $11.00, for a total value of $264,000.00. Following the transaction, the senior vice president owned 336,918 shares of the company's stock, valued at approximately $3,706,098. This trade represents a 6.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 6.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Aquatic Capital Management LLC purchased a new stake in shares of Theravance Biopharma in the 4th quarter valued at approximately $25,000. GAMMA Investing LLC lifted its holdings in shares of Theravance Biopharma by 1,201.8% in the first quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 3,281 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Theravance Biopharma in the fourth quarter worth $69,000. AQR Capital Management LLC purchased a new position in shares of Theravance Biopharma during the first quarter valued at $101,000. Finally, Teacher Retirement System of Texas acquired a new position in Theravance Biopharma during the fourth quarter valued at $103,000. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.